Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. [electronic resource]
Producer: 20170501Description: 1805-1811 p. digitalISSN:- 1879-1913
- Acute Coronary Syndrome -- epidemiology
- Aged
- Angina, Unstable -- epidemiology
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents -- adverse effects
- Back Pain -- chemically induced
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Comorbidity
- Coronary Disease -- epidemiology
- Diabetes Mellitus, Type 2 -- epidemiology
- Ezetimibe -- adverse effects
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors -- therapeutic use
- Hypercholesterolemia -- drug therapy
- Influenza, Human -- chemically induced
- Middle Aged
- Myocardial Infarction -- epidemiology
- Nasopharyngitis -- chemically induced
- Pruritus -- chemically induced
- Randomized Controlled Trials as Topic
- Respiratory Tract Infections -- chemically induced
- Stroke -- epidemiology
- Urinary Tract Infections -- chemically induced
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.